PSA VELOCITY IN MEN STARTING 5-ALPHA- REDUCTASE INHIBITORS AT THE TIME OF STARTING ACTIVE SURVEILLANCE IS A PREDICTOR OF PATHOLOGICAL PROGRESSION IN LOW-RISK PROSTATE CANCER

被引：0
|
作者：
Timilshina, Narhari
Alibhai, Shabbir
Komisarenko, Maria
Martin, Lisa
Grewal, Ruby
Hamilton, Rob
Kulkarni, Girish
Zlotta, Alexandre
Fleshner, Neil
Finelli, Antonio
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.02.2429
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD55-06
引用
收藏
页码：E1053 / E1053
页数：1
相关论文
共 50 条
  • [1] 5-alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on active surveillance
    Finelli, A.
    Trottier, G.
    Lawrentschuk, N.
    Sowerby, R. J.
    Zlotta, A. R.
    Radomski, L.
    Timilshina, N.
    Evans, A.
    Van der Kwast, T. H.
    Toi, A.
    Jewett, M. A. S.
    Trachtenberg, J.
    Fleshner, N. E.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E1092 - U273
  • [2] 5-ALPHA REDUCTASE INHIBITORS DIMINISH THE RATE OF PROGRESSION IN MEN WITH LOW RISK PROSTATE CANCER ON ACTIVE SURVEILLANCE
    Finelli, Antonio
    Trottier, Greg
    Lawrentschuk, Nathan
    Sowerby, Robert J.
    Zlotta, Alexandre R.
    Radomski, Lenny
    Timilshina, Narhari
    Evans, Andrew
    van der Kwast, Theodorus H.
    Toi, Ants
    Jewett, Micheal A. S.
    Trachtenberg, John
    Fleshner, Neil E.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E715 - E715
  • [3] Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer
    Chiang, Andrew Szehsun
    Loblaw, D. Andrew
    Jethava, Vibhuti
    Sethukavalan, Perakaa
    Zhang, Liying
    Vesprini, Danny
    Mamedov, Alexandre
    Nam, Robert
    Klotz, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [4] Association of PSA Velocity with Disease Progression and Metastases in Men with Low Risk Prostate Cancer on Active Surveillance
    Nelson, T. J.
    Deka, R.
    Nalawade, V.
    Chen, Q.
    Courtney, P. T.
    Salans, M. A.
    Cherry, D. R.
    Luterstein, E.
    Parsons, J. K.
    Kader, K.
    Stewart, T. F.
    Mell, L. K.
    Murphy, J. D.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E881 - E881
  • [5] 5-ALPHA-REDUCTASE INHIBITORS IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
    Dai, Charles
    Ganesan, Vishnu
    Zabell, Joseph
    Nyame, Yaw
    Hettel, Daniel
    Almassi, Nima
    Greene, Daniel
    Haywood, Samuel
    Reichard, Chad
    Zampini, Anna
    Crane, Alice
    Arora, Hans
    El-Shafei, Ahmed
    Stein, Robert
    Fareed, Khaled
    Gong, Michael
    Jones, J. Stephen
    Stephenson, Andrew
    Klein, Eric
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E229 - E229
  • [6] Active surveillance for men with low-risk prostate cancer
    Sturch, Paul
    Kirby, Roger
    Challacombe, Ben
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (02) : 14 - 16
  • [7] Is PSA doubling time reliable as a progression criterion in the monitoring of low-risk prostate cancer followed on active surveillance?
    Thomsen, Frederik Birkebaek
    Christensen, Ib Jarle
    Roder, Martin Andreas
    Brasso, Klaus
    Iversen, Peter
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2013, 47 : 16 - 17
  • [8] Active Surveillance for Black Men With Low-Risk Prostate Cancer
    Shen, Xinglei
    Pettaway, Curtis A.
    Chen, Ronald C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (17): : 1733 - 1734
  • [9] THE QUALITY OF ACTIVE SURVEILLANCE FOR MEN WITH LOW-RISK PROSTATE CANCER
    Levy, Mya E.
    Meyers, Stephanie
    Wood, David P.
    Montie, James E.
    Miller, David C.
    Wei, John T.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 179 - 179
  • [10] Active Surveillance for Patients with Low-Risk Prostate Cancer: How Does PSA Doubling Time Affect the Risk of Histo-Pathological Progression at Re-Biopsy?
    Thomsen, F.
    Roder, M.
    Hvarness, H.
    Iversen, P.
    Brasso, K.
    [J]. UROLOGY, 2012, 80 (03) : S26 - S26
12345